DaltonTx has announced its exit from stealth and the completion of a £4m seed financing round to build adaptive, AI-enabled discovery platforms that will reshape the economics, timelines and outcomes of R&D, enabling breakthrough medicines to reach patients faster.
AI offers pharma a unique opportunity to discover medicines more effectively and efficiently.
However, building adaptive AI platforms requires years of investment in software engineering, coupled with a deep understanding of the science and technology behind the AI framework.
DaltonTx solves this with a disease- and technology-agnostic adaptive platform that can plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery instead of spending years developing these capabilities in-house.
The platform has been built by scientists for scientists, going beyond predictive modelling to power the full discovery process — from raw data and model training to molecular design, synthesis and decision-making.
DaltonTx is adaptive rather than predictive, making it a reasoning engine that learns from every scientist, model and experiment to continuously improve outcomes.
Born from decades of real-world experience, DaltonTx was co-founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley and Professor Charlotte Deane MBE.
Together, the team combines expertise in areas including drug discovery, machine learning and software engineering, having built pioneering AI discovery platforms at AstraZeneca and Exscientia and bringing world-leading academic research from the University of Oxford.
"AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities," said Dr Garry Pairaudeau, co-founder of DaltonTx, "DaltonTx exists to change that."
"We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment and give organisations lasting AI capability."
Its platform is purpose-built for both small molecules and biologics, making it uniquely suited to support the most complex R&D pipelines.
Additionally, DaltonTx enables collaborative intelligence: scientists can interact with the system, combining their expertise with an engine that iterates and learns, combining human insight and machine learning to work together.
"At DaltonTx, we're generating biological and chemical insight that was previously out of reach," said Professor Charlotte Deane MBE, co-founder of DaltonTx and Professor of Structural Bioinformatics at the University of Oxford.
"By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact."
With the seed funding from redalpine, IQ Capital Partners and Seedcamp, as well as support from Oxford University Innovation, DaltonTx will now be able to redefine how technology can transform drug discovery.
"DaltonTx is poised to become the intelligence backbone of drug discovery, providing scientific reasoning capabilities and deep integration into real drug discovery workflows."
"Led by a highly impressive team of industry experts, we believe the DaltonTx platform will soon be indispensable for every R&D organisation across pharma, biotech and CROs," said Marc Moesser, Investment Manager at redalpine.
"What impressed us most about DaltonTx is the strength and depth of the founding team," added Tom Wilson, Partner, Seedcamp.
"Their unique combination of drug discovery, machine learning and software engineering expertise positions them to lead the next generation of AI in pharma."
"We're proud to back a team with the vision and execution capability to transform how medicines are discovered."